Ποια είναι η τιμή για Venus Medtech (Hangzhou) Inc. (2500)

Η τιμή για Venus Medtech (Hangzhou) Inc. (2500) είναι $0.13048475

Ποια είναι η κεφαλαιοποίηση αγοράς για Venus Medtech (Hangzhou) Inc. (2500)

Η κεφαλαιοποίηση αγοράς για Venus Medtech (Hangzhou) Inc. (2500) είναι $57.55M

Venus Medtech (Hangzhou) Inc. (2500) Τιμή και Κεφαλαιοποίηση Αγοράς

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.

Η τιμή για 2500	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$11,838.36 $57.55M	NVDA	$5.221T	+9,072,497.72%
$10,282.24 $57.55M	AAPL	$4.535T	+7,879,933.78%
$9,405.36 $57.55M	GOOG	$4.148T	+7,207,913.93%
$8,130.87 $57.55M	MSFT	$3.586T	+6,231,181.77%
$6,303.12 $57.55M	AMZN	$2.780T	+4,830,444.42%

Η τιμή για 2500

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$11,838.36 $57.55M